Ann: BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS, page-225

Yes, "completed" phase 2 is what I read from the website. Sorry if I read it wrong?!?

Completed Human Clinical Trials:
BIT225-001 – Phase 1, single-dose, dose escalating study (n=48)
BIT225-003 – Phase 1b, HCV-infected patients (n=18)
BIT225-004 – Phase 1b/2a, HIV-1 infected patients (n=21) Trial registration on ANZCTR
BIT225-005 – Phase 2a, HCV-infected patients (n=24) Trial registration on ANZCTR
BIT225-006 – Phase 2, HIV/HCV co-infected (n=12) Trial registration on ANZCTR
BIT225-007 – Phase 1 capsule formulation, cross-over study (n=14) Trial registration on ANZCTR
BIT225-008 – Phase 2, repeat dose (n=60) Trial registration on ANZCTR